28.09.2020 • News

Solvay Adapts European Peroxides Footprint

Solvay has announced it will reshuffle its hydrogen peroxide manufacturing network in Europe, the Middle East and Africa (EMEA) to meet a shift in demand, which has been accelerated by the coronavirus pandemic.

As part of its multi-year Peroxides for the Future (P4F) program, Solvay will cut its production capacity in Western Europe by 70,000 t/y as of Jan. 1, 2021. The company did not disclose at which locations it will reduce output.

However, it did does operate 10 plants in EMEA, including at Jemeppe-sur-Sambre, Belgium; Bernburg, Germany; and Voikkaa, Finland, where the company announced in July 2019 that it would expand capacity to meet rising demand in both existing and new applications.

The Belgian-based group also plans to establish production centers in new areas, closer to new pockets of demand, by using proprietary technologies, in particular MyH202, which are mini satellite plants located on customers’ sites. In addition, Solvay intends to leverage digital solutions to increase the efficiency of its supply chain.

While the overall hydrogen peroxide market remains strong, certain market segments and sub-regions have reacted differently to the Covid-19 crisis. For example, traditional segments such as printing and writing are seeing their decline accelerate while other applications’ growth has been boosted, the company said.

 

Author: Elaine Burridge, Freelance Journalist

Solvay will reshuffle its hydrogen peroxide manufacturing network in Europe,...
Solvay will reshuffle its hydrogen peroxide manufacturing network in Europe, the Middle East and Africa to meet shifting demand, accelerated by Covid-19. Under its multi-year Peroxides for the Future program, Solvay will cut West European output by 70,000 t/y from Jan. 1, 2021. (c) Solvay

Company

Logo:

Solvay

Rue du Prince Albert 33
1050 Bruxelles
Belgium

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read